Actim is developing three SARS-CoV-2 tests to detect COVID-19 infection to help restrict the pandemic:
- Serological antibody detection ELISA for efficient mass testing of recent infection
- Serological antibody detection rapid test for immediate detection of recent infection
- SARS-CoV-2 virus antigen detection rapid test for immediate diagnosis of active infection
Efficient mass testing of recent COVID-19 infection
Actim ELISA SARS-CoV-2 IgG/IgM
The Actim ELISA SARS-CoV-2 IgG/IgM test is a serological antibody detection test that detects recent COVID-19 infection by recognizing the IgG and IgM antibodies produced by the immune system which are specific to the SARS-CoV-2 virus.
The ELISA (enzyme-linked immunosorbent assay) test is based on the attachment of antibodies from a sample of venous blood serum to antigens on a test plate. Dozens of samples can be tested at once, making mass testing fast and efficient. The results, ready in hours, indicate the level of SARS-CoV-2 antibodies in the sample.
The test plates and reagents are developed and produced in Finland and the first batches will be available for testing in August 2020.
Immediate detection of recent COVID-19 infection
Actim SARS-CoV-2 IgG/IgM
Actim SARS-CoV-2 IgG/IgM is a serological antibody detection test that diagnoses past COVID-19 infection immediately with convenient sample collection.
The test is a qualitative immunochromatographic dipstick test based on immobilized antigens capturing SARS-CoV-2 specific antibodies in the sample. Only a drop of blood from the fingertip is needed and the results are ready in minutes. The testing is easy as no laboratory facilities are needed.
The test is developed and produced in Finland and the first batch will be available for testing in September 2020.
Diagnosis of active COVID-19 without delay
Actim SARS-CoV-2 test is a virus antigen detection rapid test to diagnose a current COVID-19 infection on the spot.
The test is a qualitative immunochromatographic test based on detecting of SARS-Cov-2 virus antigens in the nasal swab sample. Unlike PCR-based COVID-19 tests, the Actim rapid test does not require laboratory facilities or sample processing, and the results are ready in minutes.
The test is developed and produced in Finland and the first batches will be available for testing in September 2020.
The serological tests detect past COVID-19 infections by recognizing SARS-CoV-2 specific immunoglobulins (IgG or/and IgM) produced by the immune system approximately 2–3 weeks after the onset of the infection.
The antigen test diagnoses acute COVID-19 infections by recognizing viral particles directly. The test is based on antibodies specific to antigens of the SARS-CoV-2 virus found in nasal mucous during infection. The immediate COVID-19 diagnosis allows early initiation of appropriate treatment and preventive actions to limit the spread of the pandemic.